BuzzSparks.org

Receptos


Drug Discovery Company

Receptos is a privately-held drug discovery and development company which utilizes pioneering G protein-coupled receptor (GPCR) technology to facilitate information-driven drug design for developing best- and first-in-class drugs.

Founded in 2007
Homepage:
Total money raised: $73.5M

92121 10835 Road to the Cure
Suite #205

San Diego
USA CA

Phone: (858) 652-5700

Updated on Mar 20, 2014
Receptos at CrunchBase
Robert J. Peach Chief Scientific Officer and Founder
Faheem Hasnain President & CEO
Marcus F. Boehm Chief Technology Officer and Founder
Graham Cooper Chief Financial Officer
Christian Waage Senior Vice President and General Counsel
Chrysa Mineo Vice President, Corporate Development
James R. Schmidt Vice President, Finance and Administration
Amir Nashat Board of Directors
Sheila Gujrathi Chief Medical Officer
Doug Cole Board of Directors
Erle T. Mast Board of Directors
William Rastetter Chairman and Founder
Amir Nashat Board of Directors
Kristina Burrow Board of Directors
S. Edward Torres Board of Directors
Past
William Rastetter Acting Chief Executive Officer
Marcus F. Boehm Vice President of Chemistry
Robert J. Peach Vice President of Biology

May, 2013

Receptos IPO
Stock symbol: NASDAQ:RCPT

March, 2012

Receptos raised $30M in unattributed round from Osage University Partners, ARCH Venture Partners, Flagship Ventures, Lilly Ventures, OrbiMed Advisors, and Venrock

February, 2012

Receptos raised $10.8M in partial round

SEC    sec.gov

November, 2009

Receptos raised $25M in a Series A round from ARCH Venture Partners, Flagship Ventures, Lilly Ventures, and Venrock

Receptos raises $25M in Series A    fiercebiotech.com

May, 2009

Receptos raised $7.7M in unattributed round

SEC    sec.gov

2007

Receptos was founded in 2007